WTiNT is under clinical development by Eutilex and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Glioblastoma Multiforme (GBM) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how WTiNT’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
WTiNT is under development for the treatment of recurrent solid tumors such as glioblastoma. The therapeutic candidate constitutes autologous Wilms tumor protein 1 (WT1)-specific CD8 positive T cells. It acts by targeting tumor cells expressing WT1. It is based on 4-1 BB CTL Adoptive T cell therapy. It was also under development for the treatment of leukemia. It is administered through intravenous route.
Eutilex Co. Ltd., a clinical-stage biopharmaceutical company that develops immunotherapy technology, anti tumor T cell therapy and antibody therapeutics, and other technology products. The company is headquartered in Republic of Korea (South Korea).
For a complete picture of WTiNT’s drug-specific PTSR and LoA scores, buy the report here.